MX2021011598A - Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. - Google Patents

Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.

Info

Publication number
MX2021011598A
MX2021011598A MX2021011598A MX2021011598A MX2021011598A MX 2021011598 A MX2021011598 A MX 2021011598A MX 2021011598 A MX2021011598 A MX 2021011598A MX 2021011598 A MX2021011598 A MX 2021011598A MX 2021011598 A MX2021011598 A MX 2021011598A
Authority
MX
Mexico
Prior art keywords
patient
microrna
mir128
mir101
seizure disorder
Prior art date
Application number
MX2021011598A
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2021011598A publication Critical patent/MX2021011598A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan métodos para tratar un trastorno convulsivo en un paciente que necesita de estos, que incluyen suministrar al paciente una cantidad efectiva de una composición que aumenta el nivel de moléculas de microARN-101 en las células cerebrales del paciente. Se proporcionan métodos para tratar un trastorno convulsivo en un paciente que necesita de estos, que incluyen suministrar al paciente una cantidad efectiva de una composición que aumenta el nivel de moléculas de microARN-128 en las células cerebrales del paciente. Se proporcionan métodos para tratar un trastorno convulsivo en un paciente que necesita de estos, que incluyen administrar un vector que codifica el microARN-101, pri-miR101 o pre-miR101 al paciente. Se proporcionan métodos para tratar un trastorno convulsivo en un paciente que necesita de estos, que incluyen administrar un vector que codifica el microARN-128, pri-miR128 o pre-miR128 al paciente. En las realizaciones, los niveles aumentados de microARN-101 y/o microARN-128 causan una mejora en uno o más síntomas del trastorno convulsivo.
MX2021011598A 2017-12-06 2020-07-13 Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. MX2021011598A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762595255P 2017-12-06 2017-12-06

Publications (1)

Publication Number Publication Date
MX2021011598A true MX2021011598A (es) 2021-10-13

Family

ID=66658874

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005952A MX2020005952A (es) 2017-12-06 2018-12-06 Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MX2021011598A MX2021011598A (es) 2017-12-06 2020-07-13 Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020005952A MX2020005952A (es) 2017-12-06 2018-12-06 Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.

Country Status (10)

Country Link
US (2) US10870855B2 (es)
EP (1) EP3703820A4 (es)
JP (1) JP2021505619A (es)
KR (1) KR20200119782A (es)
CN (1) CN111417397A (es)
AU (1) AU2018378622A1 (es)
CA (1) CA3084985A1 (es)
IL (1) IL274838A (es)
MX (2) MX2020005952A (es)
WO (1) WO2019113266A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3084985A1 (en) 2017-12-06 2019-06-13 Ovid Therapeutics Inc. Use of mir101 or mir128 in the treatment of seizure disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3499437A (en) 1967-03-10 1970-03-10 Ultrasonic Systems Method and apparatus for treatment of organic structures and systems thereof with ultrasonic energy
US4303636A (en) 1974-08-20 1981-12-01 Gordon Robert T Cancer treatment
US4315514A (en) 1980-05-08 1982-02-16 William Drewes Method and apparatus for selective cell destruction
US4923437A (en) 1986-07-18 1990-05-08 Gordon Robert T Process for applying a localized magnetic or electric field
US5059415A (en) 1989-02-21 1991-10-22 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon Health Method for diagnostically imaging lesions in the brain inside a blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5438989A (en) 1990-08-10 1995-08-08 Hochman; Darryl Solid tumor, cortical function, and nerve tissue imaging methods and device
US5465718A (en) 1990-08-10 1995-11-14 Hochman; Daryl Solid tumor, cortical function, and nerve tissue imaging methods and device
US5307816A (en) 1991-08-21 1994-05-03 Kabushiki Kaisha Toshiba Thrombus resolving treatment apparatus
US5291890A (en) 1991-08-29 1994-03-08 General Electric Company Magnetic resonance surgery using heat waves produced with focussed ultrasound
US5524620A (en) 1991-11-12 1996-06-11 November Technologies Ltd. Ablation of blood thrombi by means of acoustic energy
JP3325300B2 (ja) 1992-02-28 2002-09-17 株式会社東芝 超音波治療装置
US5526814A (en) 1993-11-09 1996-06-18 General Electric Company Automatically positioned focussed energy system guided by medical imaging
US5368032A (en) 1993-11-09 1994-11-29 General Electric Company Manually positioned focussed energy system guided by medical imaging
US5443068A (en) 1994-09-26 1995-08-22 General Electric Company Mechanical positioner for magnetic resonance guided ultrasound therapy
US5752515A (en) 1996-08-21 1998-05-19 Brigham & Women's Hospital Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier
WO2007035721A2 (en) 2005-09-19 2007-03-29 The Trustees Of Columbia University In The City Of New York Ultrasound method to open blood brain barrier
WO2008137915A2 (en) * 2007-05-07 2008-11-13 Medimmune, Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2011101869A1 (en) * 2010-02-22 2011-08-25 Transgene Biotek Ltd. Adeno-associated virus 2/8 - micro rna-101 therapy for liver cancer
GB201103062D0 (en) * 2011-02-22 2011-04-06 Isis Innovation Method
GB201223244D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Gmbh Micrornas as therapeutics and biomarkers for epilepsy
CN107207597A (zh) 2014-11-06 2017-09-26 儿研所儿童医学中心 用于癌症和自身免疫疾病的免疫疗法
MX2017010369A (es) * 2015-02-10 2017-12-14 Genzyme Corp Arni variante.
US20180201937A1 (en) * 2015-08-04 2018-07-19 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
US11072804B2 (en) * 2016-02-12 2021-07-27 Combigene Ab Vector
US20190060400A1 (en) * 2017-03-15 2019-02-28 Ovid Therapeutics Inc. Use of designer receptors exclusively activated by designer drugs and ultrasound in the treatment of seizure disorders
CA3084985A1 (en) 2017-12-06 2019-06-13 Ovid Therapeutics Inc. Use of mir101 or mir128 in the treatment of seizure disorders

Also Published As

Publication number Publication date
EP3703820A4 (en) 2020-12-09
US10870855B2 (en) 2020-12-22
WO2019113266A1 (en) 2019-06-13
AU2018378622A1 (en) 2020-05-28
MX2020005952A (es) 2022-01-03
US11761006B2 (en) 2023-09-19
EP3703820A1 (en) 2020-09-09
JP2021505619A (ja) 2021-02-18
US20190169619A1 (en) 2019-06-06
IL274838A (en) 2020-07-30
CN111417397A (zh) 2020-07-14
US20210095292A1 (en) 2021-04-01
CA3084985A1 (en) 2019-06-13
KR20200119782A (ko) 2020-10-20

Similar Documents

Publication Publication Date Title
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12017500680A1 (en) Compositions and methods of use for treating metabolic disorders
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
PH12017502103A1 (en) Methods and kits for treating depression
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
MX2018013663A (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
SG10201902664RA (en) Combination therapy for treating cancer
MX2020006654A (es) Métodos intraductales de tratamiento de trastornos de mama.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MY201804A (en) Administration and dosage of diaminophenothiazines
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
EA201991650A1 (ru) Способы лечения неврологических расстройств
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2019010982A (es) Uso de receptores de diseño activados exclusivamente mediante fármacos de diseño en el tratamiento de trastornos convulsivos.
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
EA201691567A1 (ru) Способы лечения легких травм головного мозга
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2019006141A (es) Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2021011598A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.